HMC
IRLA

Harvard Management Company’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Harvard Management Company’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15
Closed -$156K – 46
2021
Q2 		$156K Buy
+15
New +$126K 0.01% 38

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Harvard Management Company's IRLA Position: Q3 2021 in Review

Harvard Management Company sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2021, closing a stake of 15 shares — an estimated $156K sold.

Harvard Management Company first reported a position in IRLA in Q2 2021 and held it in 1 quarter. The position peaked at $156K in Q2 2021. 126 funds tracked by Wall St. Rank hold IRLA as of Q3 2021.

  • Harvard Management Company reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Harvard Management Company sold 15 IRulya Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $156K.
  • Harvard Management Company first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Harvard Management Company's IRulya Therapeutics Inc. Common Stock position peaked at $156K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2021.

Based on Harvard Management Company's 13F filing for Q3 2021, filed 12 Nov 2021.